In tumor-associated DCs, combined applications of TLR7/8 agonists and STAT3 inhibitors effectively enhance the antigen uptake and presentation by DCs, which thus promotes DC migration to lymph nodes and augments the antigen-specific cytotoxic activity of CD8+ T cells (88). Here, TLR7 is linked to neoplasm.